|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.
|
17379860 |
2007 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subjective improvement in OSA symptoms was reported by all patients and objective PSG improvement was reported for 71% of those evaluated.
|
30639150 |
2019 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the traditional PSG-based OSA detection, people's sleep may be disturbed, meanwhile the electrode slices are easily to fall off.
|
31499731 |
2019 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 90 patients were enrolled into the study, 50 subjects were divided into OSA groups and 40 in healthy control according to PSG examination.
|
29843666 |
2018 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical and PSG factors were examined as predictors of OSA.
|
29880147 |
2018 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
A second PSG study performed 2 months postoperatively to confirm OSA resolution, and those with residual OSA were excluded.
|
30368376 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surprisingly, RSWA values in PSG with melatonin were high, probably because of the still untreated OSAS.
|
28545360 |
2017 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
The review included observational studies in the English language with a clearly established aim to assess the relationship between OSAS and SB using full-night PSG.
|
27977045 |
2017 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sleep specialists should use the SBQ to conduct patient interviews for the early diagnosis of OSA in clinical settings, particularly in resource-poor countries and sleep clinics where PSG is unavailable.
|
27919588 |
2017 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within this population, L-PSG underestimates obstructive sleep apnea and central sleep apnea compared to H-PSG.
|
28934528 |
2017 |
|
Sleep Apnea, Obstructive
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study group (PSG-confirmed OSAS) included 62 individuals, aged 51.7±10.3 years.
|
28501722 |
2017 |
|
Sleep Apnea, Obstructive
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preoperative and postoperative (6 months) physical examination, PSG, bone age (BA) and osteocalcin (OC) evaluation were performed on the selected OSA children (n=92) and the healthy children (n=87).
|
27917446 |
2017 |
|
REM Sleep Behavior Disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the clinical variations in patients with Parkinson's disease (PD) with (PDRBD) or without REM sleep behaviour disorder (RBD) (Non-RBD), and PDRBD patients were classified into Confirmed-RBD (definite diagnosis with polysomnography, PSG) and Probable-RBD (without PSG re-confirmation).
|
28091622 |
2017 |
|
REM Sleep Behavior Disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Overall, 84 of 152 PD patients (55.3%) were diagnosed with RBD after PSG evaluation.
|
28979204 |
2017 |
|
REM Sleep Behavior Disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this review, we summarized the clinical and PSG features of RBD, the pathophysiology and the therapy of it, focusing on the correlation between neurodegenerative diseases and RBD, in order to emphasize the significance of RBD as an early marker of neurodegenerative diseases.
|
27032389 |
2017 |
|
REM Sleep Behavior Disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
No episode of RBD was observed in the V-PSG recordings, and no patients showed rapid eye movement (REM) sleep without atonia.
|
25845698 |
2015 |
|
Cataplexy
|
0.020 |
Biomarker
|
disease |
BEFREE |
To validate polysomnographic markers (sleep latency and sleep-onset REM periods [SOREMPs] at the Multiple Sleep Latency Test [MSLT] and nocturnal polysomnography [PSG]) for pediatric narcolepsy type 1 (NT1) against CSF hypocretin-1 (hcrt-1) deficiency and presence of cataplexy, as no criteria are currently validated in children.
|
31405906 |
2019 |
|
Somnolence
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Further study is required to assess if REM EEG slowing related to nocturnal hypoxemia is more sensitive than standard PSG indices or sleepiness in predicting cognitive decline.
|
31004167 |
2019 |
|
Narcolepsy type 1
|
0.020 |
Biomarker
|
disease |
BEFREE |
To validate polysomnographic markers (sleep latency and sleep-onset REM periods [SOREMPs] at the Multiple Sleep Latency Test [MSLT] and nocturnal polysomnography [PSG]) for pediatric narcolepsy type 1 (NT1) against CSF hypocretin-1 (hcrt-1) deficiency and presence of cataplexy, as no criteria are currently validated in children.
|
31405906 |
2019 |
|
Apnea+hypopnea
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
At 24 months, 79% had an apnea-hypopnea- index (AHI) > 1 events/hour at PSG, with a mean AHI of 3.00 ± 2.95.
|
30466820 |
2019 |
|
Narcolepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Standard PSG/MSLT criteria were used to diagnose hypersomnia/narcolepsy.
|
29116485 |
2018 |
|
Sleeplessness
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We concluded that individuals who had sought help for both insomnia and snoring showed impaired sleep in terms of PSG and that this was not reflected in ratings of sleep or health.
|
30099355 |
2018 |
|
Sleeplessness
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The Relationship Between PSG and Morning/Evening Emotional Parameters in Patients With Insomnia Disorder and Good Sleepers.
|
30687172 |
2018 |